StockData
Provectus Biopharmaceuticals, Inc. logo

Provectus Biopharmaceuticals, Inc. (PVCT) income statement

PVCTOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 4/30
$0.05+0.00 (+0.39%)

Close on Oct 19, 2026Market cap $20.55MP/E –Yield –

Provectus Biopharmaceuticals, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin
–
Operating margin
-1363.5%
Net margin
-1413.0%
Return on equity, FY2025
88.6%

Financial strength

Current ratio
0.18
Debt to equity
–
Debt to assets
–
Cash to current liabilities
15.0%

Valuation

P/E ratio
–
Price to sales
61.15
Price to book
–
Dividend yield
–

See a number that looks wrong?